REGULATORY

• Japan PM Pins Hope for Leadership of Kamoshita as Drug Policy Advisor
  November 2, 2023

• MHLW to Consider Investigation on OTC Drug Abuse: Minister
  November 2, 2023

• Organization to Push Drug Discovery Is One Option: Health Minister
  November 1, 2023

• Basic Dementia Law Set to Take Effect on January 1: MHLW
  November 1, 2023

• Japan Economic Package to Call for Boosting Innovation for Next-Gen Biologics
  November 1, 2023

• Cases of Unintentional Xocova Use in Pregnant Women Total 32: MHLW
  October 31, 2023

• AMED, Europe’s HERA to Cooperate in Medical Countermeasures
  October 31, 2023

• PMDA Investigating Safety Risks of Eliquis, Other Anticoagulants for Acute Kidney Injury
  October 30, 2023

• No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
  October 30, 2023

• Medical, Long-Term Care Data Linkage Holds Key to CEA: Leqembi Debate
  October 30, 2023

• Panel OKs Xarelto’s Label Expansion for Post-Fontan Heart Failure Patients
  October 30, 2023

• Lawmakers Demand NIP Coverage for Male Use of 4-Valent HPV Vaccine
  October 26, 2023

• Japan’s Healthcare Spending Hits 45 Trillion Yen in FY2021
  October 26, 2023

• Japan to Push 2024 Reform Debate by Using Price “Maintenance” and “Raise” Rules: PM
  October 26, 2023

• Japan to Deliberate Pricing Measures for Stable Drug Supplies: Draft Economic Package
  October 25, 2023

• Sawai’s Misconduct Severely Undermines Credibility of Generics: Health Minister
  October 25, 2023

• Panel Approves Revision to Basic Blood Product Policy; Change to Take Effect Next April
  October 24, 2023

• Japan PM Vows to Review Official Prices, Eyeing Wage Hikes
  October 24, 2023

• Japan Panel Clears Additional Usages for Adcetris, Opdivo, and More
  October 24, 2023

• PMDA’s New Mid-Term Plan to Push Pediatric, Orphan Drug Development to Counter Losses
  October 23, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 66
• 67
• 68
• 69
• 70
• 71
• 72
• 73
• 74
• …
• Next ›
• 最終 »